This work focused on the development of a concentric multi-layered fixed-dose combination via an advanced manufacturing technique, hot-melt co-extrusion. The dosage form was designed to offer differing release behaviour; immediate and sustained release from the coat and core, respectively. Hydrochlorothiazide and losartan potassium were incorporated as anti-hypertensive drugs. Solid-state characterisation revealed that both were transformed into their amorphous forms. In-vitro dissolution testing showed desired release performances offering both immediate and modified release.
Fixed-dose combinations, hot-melt co-extrusion, hypertension
How to CiteAlmajaan A. , Healy A. , Jones D. , Gilvary G. , Andrews G. P. , Kelleher J. F. , Li S. , Tian Y. & Senta-Loys Z. (2019) “Hot-melt co-extrusion technology as a manufacturing platform for anti-hypertensive fixed-dose combinations”, British Journal of Pharmacy. 4(1). doi: https://doi.org/10.5920/bjpharm.596